Professor, Internal Medicine, Mayo Medical School
Hematology
Dr. Angela Dispenzieri, MD
|
|
Give Review
Angela Dispenzieri is an expert in the field of Hematology. He researched medicine at Albert Einstein College of Medicine of Yeshiva University. Angela Dispenzieri is also a published MD. He has 99 paper published. The most recent paper is: The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. He is registered with Medicare and accepts Medicare payments.
Publications
- Outcomes of primary refractory multiple Myeloma and the impact of novel therapies.
- Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study.
- Blaming the Right Fluorescent in Situ Hybridization.
- Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple Myeloma.
- Treatment outcomes, healthcare resource utilization, and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myel...
- Correlation of Histomorphologic Pattern of Cardiac Amyloid Deposition with Amyloid Type: A Histologic and Proteomic Analysis of 108 Cases.
- New Cancers after autotransplantations for multiple myeloma.
- Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab.
- Soluble suppression of tumorigenicity 2 (sST2), but not Galactin-3, adds to prognostication in patients with Systemic AL amyloidosis independent of NT-proBNP and Tropo...
- Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
- Elevation of serum immunoglobulin free light chains during the preclinical period of rheumatoid arthritis.
- Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
- Diagnosis of monoclonal gammopathy of renal significance.
- Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome.
- Multiple Myeloma after kidney transplantation.
- Natural history and therapy of AL cardiac amyloidosis.
- International Myeloma Working Group updated criteria for the diagnosis of multiple Myeloma.
- Impact of Pre-transplant Therapy and Depth of Disease Response prior to Autologous Transplantation for Multiple Myeloma.
- Clinical course of light-chain smouldering multiple Myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study.
- Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple Myeloma.
- Pathophysiology and treatment of cardiac amyloidosis.
- Clinical characteristics and healthcare utilization of patients with multicentric Castleman Disease.
- Lenalidomide and dexamethasone in transplant-ineligible patients with Myeloma.
- Frequencies and Geographic Distributions of Genetic Mutations in Transthyretin- and Non-Transthyretin-Related Familial Amyloidosis.
- Computed tomography assessment of bone lesions in patients with POEMS syndrome.
- Older Patients with Myeloma Derive Similar Benefit from Autologous Transplantation.
- Long-term outcome of patients with multiple Myeloma-related advanced renal failure following auto-SCT.
- Clinical diagnosis and typing of Systemic amyloidosis in subcutaneous fat aspirates by mass spectrometry-based proteomics.
- Trends in survival of patients with primary plasma cell Leukemia: a population based analysis.
- Accuracy of self-reported tobacco use status among hematopoietic SCT patients.
- Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction.
- Multiple Myeloma in the Very Old: An IASIA Conference Report.
- Long-term Disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
- Quantification of clonal circulating plasma cells in newly diagnosed multiple Myeloma: implications for redefining high-risk Myeloma.
- Monitoring M-Proteins in Patients with Multiple Myeloma Using Heavy-Chain Variable Region Clonotypic Peptides and LC-MS/MS.
- Yield of Noncardiac Biopsy for the Diagnosis of Transthyretin Cardiac Amyloidosis.
- High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis.
- Using Mass Spectrometry to Monitor Monoclonal Immunoglobulins in Patients with a Monoclonal Gammopathy.
- POEMS syndrome: 2014 Update on diagnosis, risk-stratification, and management.
- Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
- IMWG consensus on risk stratification in multiple Myeloma.
- Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12â482 persons from the National Health and Nutritional Examination Survey.
- Clinical epidemiology and treatment patterns of patients with multicentric Castleman Disease: results from two US treatment centres.
- Advanced Cardiac Amyloidosis Associated with Normal Interventricular Septal Thickness: An Uncommon Presentation of Infiltrative Cardiomyopathy.
- Mass spectrometry-based proteomics reveals that leukocyte cell-derived chemotaxin 2 associated amyloidosis is a frequent cause of hepatic amyloidosis in the United Sta...
- Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma.
- Second transplants for multiple Myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation.
- How I treat monoclonal gammopathy of renal significance (MGRS).
- Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple Myeloma following lenalidomide-based initial therapy.
- Prediction of Poor Mobilization of Autologous CD34+ Cells with Growth Factor in Multiple Myeloma Patients: Implications for Risk-Stratification.
- Long term response to lenalidomide in patients with newly diagnosed multiple Myeloma.
- Continued improvement in survival in multiple Myeloma: changes in early mortality and outcomes in older patients.
- Smoldering multiple Myeloma requiring treatment: time for a new definition?
- Low Levels of Interleukin-1 Receptor Antagonist (IL-1RA) Predict EnGraftment Syndrome after Autologous Stem Cell Transplantation in POEMS Syndrome and Other Plasma Cel...
- Treatment trade-offs in Myeloma: A survey of consecutive patients about contemporary maintenance strategies.
- Relationship between initial clinical presentation and the molecular cytogenetic classification of Myeloma.
- Trends in Utilization and Outcomes of Autologous Transplantation as Early Therapy for Multiple Myeloma.
- Incidence of Supraventricular Arrhythmias during Autologous Peripheral Blood Stem Cell Transplantation.
- Implications of continued response after autologous stem cell transplantation for multiple Myeloma.
- A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
- Left ventricular device implantation for advanced cardiac amyloidosis.
- Outcomes of patients with POEMS syndrome treated initially with radiation.
- Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple Myeloma.
- Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myelom...
- Management of newly diagnosed symptomatic multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
- Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.
- Serum free light chain ratio as a biomarker for high-risk smoldering multiple Myeloma.
- Second auto-SCT for treatment of relapsed multiple Myeloma.
- High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple Myeloma.
- Using clinically approved cyclophosphamide regimens to control the humoral Immune response to oncolytic viruses.
- Impact of Primary Molecular Cytogenetic Abnormalities and Risk of Progression in Smoldering Multiple Myeloma.
- Risk of Acute Leukemia and Myelodysplastic Syndromes in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): a Population-Based Study of 17 315 Pat...
- Uncovering the biology of multiple Myeloma among African Americans: a comprehensive genomics approach.
- Implantable Cardioverter Defibrillators in Patients with Cardiac Amyloidosis.
- Systemic amyloidosis associated with chronic lymphocytic Leukemia/small lymphocytic lymphoma.
- Salvage Second Hematopoietic Cell Transplantation in Myeloma.
- Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
- The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
- Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
- A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple Myeloma.
- A case of peripheral nerve microvasculitis associated with multiple Myeloma and bortezomib treatment.
- Localized insulin-derived amyloidosis: A potential pitfall in the diagnosis of Systemic amyloidosis by fat aspirate.
- Long-Term Outcomes After Autologous Stem Cell Transplantation in Patients With POEMS Syndrome.
- Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases.
- Attenuated oncolytic measles virus strains as Cancer therapeutics.
- Trends and outcomes of modern staging of solitary plasmacytoma of bone.
- What do I need to know about immunoglobulin light chain (AL) amyloidosis?
- The clinical spectrum of Castleman's Disease.
- Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
- Successful use of cyclophosphamide, bortezomib, and dexamethasone to treat a case of relapsed POEMS.
- Clinicopathologic correlations in multiple Myeloma: a case series of 190 patients with kidney biopsies.
- Uniform demyelination and more severe axonal loss distinguish POEMS syndrome from CIDP.
- Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials.
- Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple Myeloma or monoclonal gammopathy of undetermined significance.
- Impact of risk stratification on outcome among patients with multiple Myeloma receiving initial therapy with lenalidomide and dexamethasone.
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple Myeloma: a prospective study.
- 'Hypersynchronisation' by tissue velocity imaging in patients with cardiac amyloidosis.
- The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple Myeloma.
Schools
Albert Einstein College of Medicine of Yeshiva University
Mayo Clinic Rochester
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Choice Plus POS II
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Blue Cross Accord
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Choice Care PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Options PPO
Education
-
Mayo School of Graduate Medical Education -
Albert Einstein College of Medicine of Yeshiva University
Hospital
-
Mayo Clinic - Rochester, Minnesota
Drug Facts
| NPI NUMBER | 1235115023 | |
| NPPES Provider LastName | DISPENZIERI | |
| NPPES Provider FirstName | ANGELA | |
| NPPES Provider ZIPCode | 559050001 | |
| NPPES Provider State | MN | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 429.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1235115023 |
| Last Name Of The Provider | DISPENZIERI |
| First Name Of The Provider | ANGELA |
| View All |
Similar Doctors
|
|
Dr. Charles Erlichman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian A. Costello, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aref Al-Kali, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca F. McClure, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William L. Nichols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott H. Kaufmann, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Michaela S. Banck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis F. Porrata, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katharine A. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Krishna A. Patel, MD |
|
|
Dr. Muhammad A. Mir, MD |